G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 102 filers reported holding G1 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,613,240 | -45.4% | 1,120,307 | -5.5% | 0.00% | – |
| Q2 2023 | $2,952,257 | -20.6% | 1,185,645 | -14.5% | 0.00% | – |
| Q1 2023 | $3,716,886 | -54.1% | 1,386,898 | -7.1% | 0.00% | – |
| Q4 2022 | $8,104,326 | -57.3% | 1,492,509 | -1.8% | 0.00% | -100.0% |
| Q3 2022 | $18,980,000 | +180.6% | 1,519,657 | +11.0% | 0.00% | – |
| Q2 2022 | $6,763,000 | -73.0% | 1,369,281 | -58.5% | 0.00% | -100.0% |
| Q1 2022 | $25,078,000 | -25.8% | 3,299,849 | -0.3% | 0.00% | 0.0% |
| Q4 2021 | $33,799,000 | -22.3% | 3,310,212 | +2.1% | 0.00% | 0.0% |
| Q3 2021 | $43,508,000 | -38.6% | 3,242,085 | +0.4% | 0.00% | -50.0% |
| Q2 2021 | $70,862,000 | -6.5% | 3,229,766 | +2.6% | 0.00% | 0.0% |
| Q1 2021 | $75,764,000 | +45.5% | 3,148,907 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $52,056,000 | +71.3% | 2,893,593 | +10.0% | 0.00% | +100.0% |
| Q3 2020 | $30,384,000 | -53.3% | 2,630,607 | -2.0% | 0.00% | -66.7% |
| Q2 2020 | $65,111,000 | +129.1% | 2,683,923 | +4.1% | 0.00% | +200.0% |
| Q1 2020 | $28,424,000 | -58.3% | 2,579,167 | -0.0% | 0.00% | -66.7% |
| Q4 2019 | $68,199,000 | +15.8% | 2,580,359 | -0.2% | 0.00% | +50.0% |
| Q3 2019 | $58,884,000 | -22.2% | 2,584,915 | +4.7% | 0.00% | -33.3% |
| Q2 2019 | $75,681,000 | +135.3% | 2,468,415 | +27.4% | 0.00% | +200.0% |
| Q1 2019 | $32,161,000 | -14.5% | 1,937,416 | -1.3% | 0.00% | -50.0% |
| Q4 2018 | $37,604,000 | -60.8% | 1,963,714 | +6.9% | 0.00% | -50.0% |
| Q3 2018 | $96,048,000 | +30.7% | 1,836,822 | +8.7% | 0.00% | +33.3% |
| Q2 2018 | $73,462,000 | +54.8% | 1,690,360 | +32.0% | 0.00% | +50.0% |
| Q1 2018 | $47,463,000 | +220.9% | 1,281,060 | +71.9% | 0.00% | +100.0% |
| Q4 2017 | $14,790,000 | +70.2% | 745,445 | +113.5% | 0.00% | – |
| Q3 2017 | $8,692,000 | +4548.1% | 349,230 | +3160.5% | 0.00% | – |
| Q2 2017 | $187,000 | – | 10,711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |